RP — Replicel Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$0.74m
- CA$1.19m
- CA$0.35m
- 12
- 63
- 16
- 20
Annual cashflow statement for Replicel Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.95 | -1.58 | -4.07 | -0.743 | -0.312 |
| Depreciation | |||||
| Non-Cash Items | -0.275 | -0.102 | 1.88 | -0.935 | -1.13 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.445 | 0.916 | -0.324 | 0.268 | 0.027 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.78 | -0.765 | -2.51 | -1.41 | -1.41 |
| Other Investing Cash Flow Items | -0.029 | 0.011 | 0 | 0 | — |
| Change in Net Investments | |||||
| Cash from Investing Activities | -0.029 | 0.011 | 0 | 0 | — |
| Financing Cash Flow Items | 0 | 0 | 2.7 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.416 | 0.764 | 2.7 | 1.6 | 1.06 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.39 | 0.01 | 0.187 | 0.192 | -0.354 |